Elanco Scales Biologics Capabilities with Major Expansion of Kansas Manufacturing Facility

Executive Summary & Key Highlights

• Facility Expansion: Elanco Animal Health Incorporated (NYSE: ELAN) completed a 25,000-square-foot expansion at its Elwood, Kansas manufacturing facility on schedule.

• Biologics Leadership: The enhanced site quadruples monoclonal antibody (mAb) processing capacity, reinforcing Elanco’s position as one of only two animal health companies currently offering commercial mAb solutions.

• Pipeline Acceleration: The facility supports core therapeutic products, including Befrena™ (tirnovetmab) for canine allergic dermatitis and Trutect™ (formerly Canine Parvovirus Monoclonal Antibody), which achieved full approval in 2025.

• CapEx Breakdown: Represents a $120 million investment phase—incorporating a new pilot plant, quality control lab, and support infrastructure—with an additional $30 million planned through 2028 (totaling $150 million).

• Strategic Partners: Kansas City-based design-build firm Burns & McDonnell led integrated design and construction services. Local support was provided by the State of Kansas, Doniphan County, and the City of Elwood.

Strategic Infrastructure & Market Context

Elanco’s $120 million capital investment comes as demand for targeted veterinary biopharmaceuticals accelerates. Monoclonal antibodies represent a fundamental shift in veterinary medicine, adapting targeted, high-specificity therapeutic mechanisms from human health to companion animal care.

With initial customer demand for Befrena™ running two times above internal forecasts, the Elwood expansion provides the scale needed to lift supply bottlenecks, aiming for unconstrained production levels by early 2027.

This operational ramp aligns with underlying market trends. Recent market research conducted by Elanco across 1,409 U.S. pet owners indicates that veterinary healthcare remains a protected budget item, with consumers maintaining spending on high-value therapeutics despite broader inflationary pressures.

Executive & Leadership Commentary

“When we announced the expansion two years ago, we recognized that executing the most exciting pipeline in Elanco’s history required a manufacturing footprint capable of matching our innovation ambition. The expanded monoclonal antibody capacity ensures that as Elanco continues to pioneer breakthroughs in animal health, we are ready to meet pet owner and veterinarian demand with a safe and reliable supply. It also brings high demand, impactful jobs to the region.”

— Grace McArdle, Executive Vice President, Manufacturing and Quality

“Pets are integral and central to our lives and Elanco’s charge is clear to keep innovating to make life better for animals. With customer demand for Befrena two times above expectations, this expansion was key in ramping capacity to meet demand as we anticipate reaching unconstrained levels in early 2027. Our R&D and manufacturing engine is stronger than ever to deliver a consistent flow of high impact innovation to meet higher pet owner expectation of care now and into the next decade.”

— Jeff Simmons, President and CEO

“Today’s milestone reinforces Elanco’s commitment to going beyond to deliver differentiated, high impact innovation in key therapeutic areas. As we continue to draw insights from monoclonal advancements in human health, we believe that antibody-based therapies have untapped potential in animal health. With the expansion of our Elwood manufacturing site, we are now better positioned to scale the future of our innovation portfolio.”

— Dr. Ellen de Brabander, Executive Vice President, Research, Development and Regulatory Affairs

Capacity Expansion – Breakdown